Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: The present disclosure relates to an organic electroluminescent compound, a plurality of host materials, and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure or by comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, it is possible to produce an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: The present disclosure relates to a plurality of host materials comprising a first host material comprising a compound represented by formula 1, and a second host material comprising a compound represented by formula 2, and an organic electroluminescent device comprising the same. By comprising a specific combination of compounds as host materials, it is possible to provide an organic electroluminescent device having lower driving voltage, higher luminous efficiency, higher power efficiency, and/or superior lifespan characteristics compared to conventional organic electroluminescent devices.

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: A biomarker composition includes, as an active ingredient, one or at least two polypeptides having 5 to 120 consecutive amino acids that are selected from the group consisting of an amino acid in which serine (S) at the 56th position is substituted with leucine (L), an amino acid in which serine (S) at the 8th position is substituted with asparagines (N), an amino acid in which threonine (T) at the 81st position is substituted with alanine (A), an amino acid in which valine (V) at the 88th position is substituted with alanine (A), an amino acid in which glycine (G) at the 117th position is substituted with asparatic acid (D), and an amino acid in which glutamic acid (E) at the 119th position is substituted with lysine (K), within an amino acid sequence of VHSV represented by SEQ ID NO: 1.

Abstract: Disclosed herein are a method for evaluating social intelligence and an apparatus for the same. The method includes creating multiple segmented video clips by segmenting, based on behavior recognition, an observation video sequence that captures the social interaction behavior of the target to be evaluated; and evaluating the social intelligence of the target by calculating an evaluation score based on the similarities between ground truth, created based on social interaction analysis, and the multiple segmented video clips.

Abstract: A fusion polynucleotide including a murine CMV promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell including the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector and/or the recombinant cell.

Abstract: Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.

Abstract: There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Abstract: A biomarker composition includes, as an active ingredient, one or at least two polypeptides having 5 to 120 consecutive amino acids that are selected from the group consisting of an amino acid in which serine (S) at the 56th position is substituted with leucine (L), an amino acid in which serine (S) at the 8th position is substituted with asparagines (N), an amino acid in which threonine (T) at the 81st position is substituted with alanine (A), an amino acid in which valine (V) at the 88th position is substituted with alanine (A), an amino acid in which glycine (G) at the 117th position is substituted with asparatic acid (D), and an amino acid in which glutamic acid (E) at the 119th position is substituted with lysine (K), within an amino acid sequence of VHSV represented by SEQ ID NO: 1.

Abstract: An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.

Abstract: An anti-HER2 antibody, an anti-c-Met/anti-HER2 bispecific antibody including the same, method for preparing same, and a method of preventing and/or treating a cancer using the same are provided.

Abstract: An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.

Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.

Abstract: Provided is an anti-Her3 antibody or antigen-binding fragment thereof, an anti-c-Met/anti-Her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.